Updates in Breast Cancer From ASCO 2025
Updates in Breast Cancer From ASCO 2025

Zunairah Shah, MD

5 Key Breast Cancer Clinical Trials Shaping Treatment
5 Key Breast Cancer Clinical Trials Shaping Treatment

Erika Hamilton, MD, FASCO, Sarah Cannon Research Institute

Clinical Impact of DESTINY-Breast09 in HER2+ Breast Cancer Management
Clinical Impact of DESTINY-Breast09 in HER2+ Breast Cancer Management

Arya Mariam Roy, MD, Hope Rugo, MD, FASCO

Strategic Timing for Multidisciplinary Care in Breast Cancer
Strategic Timing for Multidisciplinary Care in Breast Cancer

Jasmin Hundal, MD, Matthew Kurian, MD

Advancements in Oncology at ASCO 2025: Breast Cancer Highlights
Advancements in Oncology at ASCO 2025: Breast Cancer Highlights

Tanmayi Pai, MD

Key Takeaways From ASCO 2025 for Hormone-Receptor+ Metastatic Breast Cancer
Key Takeaways From ASCO 2025 for Hormone-Receptor+ Metastatic Breast Cancer

Komal Jhaveri, MD, FACP, Matthew Kurian, MD

Integrating Metastatic Triple-Negative Breast Cancer NCCN Guidelines Into Clinical Practice
Integrating Metastatic Triple-Negative Breast Cancer NCCN Guidelines Into Clinical Practice

Arya Mariam Roy, MD, Hope Rugo, MD, FASCO

ASCENT-04 Trial: First-Line Sacituzumab Govitecan Plus Pembrolizumab Improves PFS in PD-L1+ TNBC
ASCENT-04 Trial: First-Line Sacituzumab Govitecan Plus Pembrolizumab Improves PFS in PD-L1+ TNBC

Arya Mariam Roy, MD, Hope Rugo, MD, FASCO